Global Antibiotic Resistance Market, By Disease Type (Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections and Others), Pathogen Type (Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, Streptococcus Pneumoniae and Others), Drugs Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines and Others), End Users (Hospitals, Homecare, Specialty Clinics, Others) - Industry Trends and Forecast to 2030.
Antibiotic Resistance Market Analysis and Size
Antibiotic resistance is a significant global health concern because it reduces the effectiveness of antibiotics in treating bacterial infections. This can lead to longer and more severe illnesses, increased healthcare costs, and a higher risk of complications and death. There are several factors contributing to the development and spread of antibiotic resistance including overuse of antibiotics, bacterial mutation, and lack of new antibiotics among others.
Data Bridge Market Research analyses that the global antibiotic resistance market which was USD 8,130.00 million in 2022 is expected to reach USD 12,667.49 million by 2030, and is expected to undergo a CAGR of 5.7% during the forecast period of 2023 to 2030. “Urinary Tract Infection” dominates the product segment of global antibiotic resistance market owing to the increasing prevalence of antibiotic. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Antibiotic Resistance Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections and Others), Pathogen Type (Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, Streptococcus Pneumoniae and Others) Drugs Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines and Others), End Users (Hospitals, Homecare, Specialty Clinics, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Achaogen Inc (U.S.), Nabriva Therapeutics plc, (Ireland), BioVersys AG (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Destiny Pharma plc (U.K.), Armata Pharmaceuticals, Inc. (U.S.), West Way Health (Ireland), The Medicines Company (U.S.), Merck & Co., Inc. (Germany), Pfizer Inc. (U.S.), CARB-X (U.S.), Melinta Therapeutics LLC (U.S.), Novartis AG (Switzerland), Vertex Pharmaceuticals Incorporated (U.S.), GSK plc. (U.K.), AbbVie Inc. (U.S.) and F. Hoffmann-La Roche Ltd (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Antibiotics can be referred as the medications that are broadly utilized for the treatment of several forms of infections. Antibiotics resistance develops when infections stop reacting to the current antibiotics.
Global Antibiotic Resistance Market Dynamics
Drivers
- Increasing Prevalence of Antibiotic
The rising incidence of infections caused by antibiotic-resistant bacteria is a major driver for the antibiotic resistance market. As the effectiveness of existing antibiotics diminishes, there is a growing need for new and innovative treatment options.
- Increasing Prevalence of Hospital-Acquired Infections (HAIs)
HAIs, including those caused by antibiotic-resistant bacteria such as Methicillin-Resistant Staphylococcus Aureus (MRSA) and Carbapenem-Resistant Enterobacteriaceae (CRE), pose a significant burden on healthcare systems. The growing incidence of HAIs drives the demand for effective antibiotics and infection control measures to combat these resistant pathogens.
- Rise in Community-Acquired Infections
Rise in community-acquired infections Antibiotic-resistant infections are not limited to healthcare settings but are increasingly being observed in community-acquired infections as well. This includes infections caused by drug-resistant strains of bacteria like Streptococcus pneumoniae and Escherichia coli. The spread of these resistant strains in the community amplifies the need for novel antimicrobial treatments.
- Aging Population and Chronic Diseases
The aging population and the increasing prevalence of chronic diseases, such as diabetes and cancer, contribute to the higher susceptibility of individuals to infections. Antibiotic-resistant infections are particularly problematic in these populations, leading to an increased demand for effective treatments.
Opportunities
- Development of Novel Antibiotics
There is a significant opportunity for the development of new antibiotics that can overcome resistance mechanisms and effectively treat infections caused by drug-resistant bacteria. Targeting novel bacterial targets, exploring new drug classes, and employing innovative approaches such as combination therapies and adjuvants are areas of exploration for researchers and pharmaceutical companies.
-
Alternative Treatment Options
In addition to antibiotics, there is a growing need for alternative treatment options to combat antibiotic-resistant infections. This includes the development of antimicrobial peptides, phage therapy (using bacteriophages to target specific bacteria), immunotherapies, and other innovative approaches that can enhance the host immune response or target bacteria through different mechanisms.
Restraints/Challenges
- Limited Profitability
The economic viability of developing new antibiotics is often challenging. The availability of generic antibiotics at lower costs, coupled with the need for stewardship programs to promote responsible antibiotic use, can restrict the market potential and profitability of new antibiotics. This factor has led some pharmaceutical companies to shift their focus away from antibiotic research and development in favor of more financially attractive therapeutic areas.
-
Stringent Regulatory Requirements
The regulatory approval process for new antibiotics can be lengthy, complex, and costly. Stricter regulatory requirements for demonstrating safety and efficacy, especially in the context of antibiotic resistance, can pose challenges for companies developing new antimicrobial agents. The high costs and uncertainties associated with regulatory approval can deter investment in antibiotic research and development.
This global antibiotic resistance market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global antibiotic resistance market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In November 2022, Quadripartite launches a new platform to tackle antimicrobial resistance threat to human and animal health and ecosystems. The Antimicrobial Resistance Multi-Stakeholder Partnership Platform was launched today to ensure the growing threats and impacts of antimicrobial resistance are addressed globally
- In December 2021, Roche launches the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark
Global Antibiotic Resistance Market Scope
The global antibiotic resistance market is segmented on the basis of disease type, pathogen type, drug class and end user. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Urinary Tract Infection
- Intra-Abdominal Infections
- Blood Stream Infections
- Clostridium Difficile Infections
- Others
Pathogen Type
- Acinetobacter Baumannii
- Pseudomonas Aeruginosa
- Staphylococcus Aureus
- Streptococcus Pneumoniae
- Others
Drug Class
- Oxazolidinones
- Lipoglycopeptides
- Tetracyclines
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Antibiotic Resistance Market Regional Analysis/Insights
The antibiotic resistance market is analysed and market size insights and trends are provided by country, disease type, pathogen type, drug class, and end user as referenced above.
The countries covered in the antibiotic resistance market report are U.S., Canada and Mexico in North America, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the antibiotic resistance market because of the increasing prevalence of antibiotic in region, growing investment in healthcare infrastructure is also boosting the growth of the market.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to increasing prevalence of hospital-acquired infections (HAIs), rise in community-acquired infections, aging population and chronic diseases in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Antibiotic Resistance Market Share Analysis
The antibiotic resistance market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to antibiotic resistance market.
Some of the major players operating in the antibiotic resistance market are:
- Achaogen Inc (U.S.)
- Nabriva Therapeutics plc, (Ireland)
- BioVersys AG (Switzerland)
- Johnson & Johnson Services, Inc. (U.S.)
- Destiny Pharma plc (U.K.)
- Armata Pharmaceuticals, Inc. (U.S.)
- West Way Health (Ireland)
- The Medicines Company (U.S.)
- Merck & Co., Inc. (Germany)
- Pfizer Inc. (U.S.)
- CARB-X (U.S.)
- Melinta Therapeutics LLC (U.S.)
- Novartis AG (Switzerland)
- Vertex Pharmaceuticals Incorporated (U.S.)
- GSK plc. (U.K.)
- AbbVie Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
SKU-